Research ID
hum0197-v16Release info
Research title
Elucidation of disease state by multi-layered omics analysis
Research overview
- Aims
- Elucidation of disease biology based on trans-omics analysis, GWAS in the Japanese and trans-ethnic populations, Elucidation of the mechanism of COVID-19 severity
- Methods
- Metagenome shotgun sequencing, genome-wide association study (GWAS), small RNA-seq and eQTL analyses
- Participants/materials
- Metagenomic data of gut microbiome in the Japanese population (95 + 103 + 227 + 30 + 136 individuals)
Autoimmune pulmonary alveolar proteinosis cases: 198, Control participants: 395
Populations: Biobank Japan (n = 179,000), UK biobank (n = 361,000), ans FinnGen (n = 136,000), Phenotypes: 220
141 Japanese individuals
Metagenomic data of gut microbiome in Inflammatory Bowel Disease (35 Ulcerative Colitis and 39 Crohn's disease) and 40 Healthy controls
Intracranial germ cell tumors cases: 133, Control participants: 762
Populations: Biobank Japan (n = 161,801) and UK biobank (n = 377,583), Phenotypes: 9
PBMC from Japanese population (COVID-19: n = 30 + 43, Healthy controls: n = 31 + 44)
Microbial genome: Metagenome-Assembled Genome (MAG), Viral genome, CRISPR spacers
Metagenomic data of gut microbiome in the Japanese population (88 + 5 individuals) and healthy individuals (n = 73)
BioBank Japan (n=180,215), UK Biobank (n=377,441), and large-scale meta-analysis including the summary statistics of other cohorts [FinnGen, Breast Cancer Association Consortium (BCAC), and Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL)] for breast and prostate cancer (n=648,746 and 482,080), Phenotypes: 15 - URL
- N/A
Datasets
The list is the one this version published; each dataset's content is shown as it is now.
| Cart | Dataset ID | Type of data | Platforms | Access criteria | Date published |
|---|---|---|---|---|---|
| JGAD000290 | Metagenome |
| Controlled-access (Type I) | 2020-09-28 | |
| JGAD000363 | Metagenome |
| Controlled-access (Type I) | 2020-11-27 | |
| JGAD000427 | Metagenome |
| Controlled-access (Type I) | 2021-07-31 | |
| JGAD000532 | Metagenome |
| Controlled-access (Type I) | 2021-12-10 | |
| JGAD000649 | Metagenome |
| Controlled-access (Type I) | 2022-05-20 | |
| JGAD000650 | Metagenome |
| Controlled-access (Type I) | 2022-05-20 | |
| NHA000154 | GWAS for autoimmune pulmonary alveolar proteinosis |
| Unrestricted-access | 2020-11-27 | |
| NHA000162 | GWAS for 215 phenotypes |
| Unrestricted-access | 2021-03-22 | |
| NHA000164 | GWAS for 10 phenotypes |
| Unrestricted-access | 2021-12-21 | |
| NHA000163 | Fine-mapping for 79 phenotypes |
| Unrestricted-access | 2021-12-21 | |
| JGAD000621 | Read count data of miRNA |
| Controlled-access (Type I) | 2022-02-21 | |
| NHA000166 | eQTL data |
| Unrestricted-access | 2022-02-08 | |
| NHA000171 | GWAS for intracranial germ cell tumors |
| Unrestricted-access | 2022-06-10 | |
| NHA000173 | GWAS for 9 phenotypes |
| Unrestricted-access | 2022-06-16 | |
| JGAD000662 | Raw sequencing data of single-cell RNA-seq |
| Controlled-access (Type I) | 2022-07-19 | |
| JGAD000722 | Raw sequencing data of single-cell RNA-seq, clinical data |
| Controlled-access (Type I) | 2023-02-14 | |
| DRA014186 | MAG, Viral genome and CRISPR spacers of Microbial genome |
| Unrestricted-access | 2022-06-06 | |
| DRA014188 | MAG, Viral genome and CRISPR spacers of Microbial genome |
| Unrestricted-access | 2022-06-06 | |
| DRA014191 | MAG, Viral genome and CRISPR spacers of Microbial genome |
| Unrestricted-access | 2022-06-06 | |
| DRA014192 | MAG, Viral genome and CRISPR spacers of Microbial genome |
| Unrestricted-access | 2022-06-06 | |
| DRA006684 | MAG, Viral genome and CRISPR spacers of Microbial genome |
| Unrestricted-access | 2019-02-01 | |
| DRA014184 | MAG, Viral genome and CRISPR spacers of Microbial genome |
| Unrestricted-access | 2022-06-06 | |
| NHA000178 | MAG, Viral genome and CRISPR spacers of Microbial genome |
| Unrestricted-access | 2022-12-01 | |
| NHA000179 | MAG, Viral genome and CRISPR spacers of Microbial genome |
| Unrestricted-access | 2022-12-01 | |
| NHA000177 | MAG, Viral genome and CRISPR spacers of Microbial genome |
| Unrestricted-access | 2022-12-01 | |
| JGAD000729 | Metagenome |
| Controlled-access (Type I) | 2023-03-30 | |
| NHA000187 | GWAS for 15 phenotypes |
| Unrestricted-access | 2023-06-06 |
Data provider
- Principal investigator
- Yukinori Okada
- Affiliation
- Department of Statistical Genetics, Osaka University Graduate School of Medicine
Research projects
No research projects.
Grants
| Name | Title | Project number |
|---|---|---|
Precursory Research for Innovative Medical care (PRIME), Advanced Research & Development Programs for Medical Innovation, Japan Agency for Medical Research and Development (AMED) | Crosstalk among microbiome, host, disease, and drug discovery enhanced by statistical genetics |
|
FORCE, Advanced Research & Development Programs for Medical Innovation, Japan Agency for Medical Research and Development (AMED) | Elucidation of disease-specific microbiota and personalized medicine by metagenome-wide association studies |
|
Practical Research Project for Rare / Intractable Diseases, Japan Agency for Medical Research and Development (AMED) | Biology and in silico drug repositioning of pulmonary alveolar proteinosis using trans-layer omics analysis |
|
Practical Research Project for Allergic Diseases and Immunology, Japan Agency for Medical Research and Development (AMED) | Nucleic genome drug discovery for autoimmune diseases through in-silico and patient-oriented screening utilizing large-scale disease genetics |
|
Practical Research Project for Allergic Diseases and Immunology, Japan Agency for Medical Research and Development (AMED) | Genomic prediction medicine of rheumatoid arthritis based on comprehensive immune-omics resources |
|
Platform Program for Promotion of Genome Medicine, Japan Agency for Medical Research and Development (AMED) | Implementation of genomic prediction medicine based on statistical genetics |
|
Platform Program for Promotion of Genome Medicine, Japan Agency for Medical Research and Development (AMED) | Next-generation genomics analyses elucidates biology, personalized medicine, and drug discovery of psoriasis |
|
KAKENHI Grant-in-Aid for Scientific Research (A) | Elucidation of disease biology and tissue specificity by trans-layer omics analysis and whole-genome sequencing |
|
Related publications
| Title | DOI | Dataset ID |
|---|---|---|
Metagenome-wide association study of gut microbiome revealed novel aetiology of rheumatoid arthritis in the Japanese population. | ||
Genetic determinants of risk in autoimmune pulmonary alveolar proteinosis. | ||
A metagenome-wide association study of gut microbiome in patients with multiple sclerosis revealed novel disease pathology. | ||
A global atlas of genetic associations of 220 deep phenotypes | ||
Metagenome-wide association study revealed disease-specific landscape of the gut microbiome of systemic lupus erythematosus in Japanese | ||
Whole gut virome analysis of 476 Japanese revealed a link between phage and autoimmune disease | ||
Insights from complex trait fine-mapping across diverse populations | ||
Genetic architecture of microRNA expression and its link to complex diseases in the Japanese population. | ||
Multi-trait and cross-population genome-wide association studies across autoimmune and allergic diseases identify shared and distinct genetic components. | ||
DOCK2 is involved in the host genetics and biology of severe COVID-19 | ||
Prokaryotic and viral genomes recovered from 787 Japanese gut metagenomes revealed microbial features linked to diets, populations, and diseases | ||
Reconstruction of the personal information from human genome reads in gut metagenome sequencing data | ||
Pan-cancer and cross-population genome-wide association studies dissect shared genetic backgrounds underlying carcinogenesis | ||
Single-cell analyses and host genetics highlight the role of innate immune cells in COVID-19 severity |
Controlled access users
| Principal investigator | Affiliation | Country/Region | Research title | Period of data use | Dataset ID |
|---|---|---|---|---|---|
| Ilana Brito | Meinig School of Biomedical Engineering, Cornell University | New York, United States | Comparative metagenomics of lupus patients' microbiomes (Protocol Number IRB0144130) | 2022-05-12 – 2025-01-08 | |
| Yongxin LI | The department of Chemistry, The University of Hong Kong | China | Comparison of gut bacterial diversity and composition in MS/EAE | 2022-09-26 – 2025-06-09 | |
| Michiaki Hamada | Hamada Laboratory, Faculty of Science and Engineering, Waseda University | Japan | Construction of RNA-targeted Drug Discovery Database | 2023-01-05 – 2027-10-31 | |
| Tina Fuchs | Institute for Clinical Chemistry, Medical Faculty Mannheim, Heidelberg University | Germany | Investigating the clonality of VIREM cells in COVID-19 patients | 2024-02-26 – 2025-04-14 | |
| Koichi Matsuda | Clinical genome sequencing, The University of Tokyo | Japan | Disease Cohort Research Network for Disease Marker Exploratory Studies | 2024-06-17 – 2029-03-31 | |
| Yuhei Kirita | Department of Nephrology, Kyoto Prefectural University of Medicine | Japan | Elucidation of the Pathogenesis through Comparative Analysis of Peripheral Blood Gene Expression in IgA Nephropathy and Immune-related Diseases | 2025-07-29 – 2030-03-31 |